LloydsPharmacy to start offering osteoporosis injection service
Celesio UK is working with University Hospitals Birmingham NHS Foundation Trust and Amgen to administer Prolia® injections in its LloydsPharmacy stores.
Patients at University Hospitals Birmingham NHS Foundation Trust can now choose to receive their denosumab injections at one of three LloydsPharmacy stores in Birmingham. If they are identified as suitable by their consultant or specialist nurse, patients can make an appointment at LloydsPharmacy, where a specially trained pharmacist will administer the treatment.
denosumab is used to treat osteoporosis, a condition in which bones become weak and break easily. The injection treatment is for those that have an increased risk of bone fracture, Jill Pritchard, head of speciality pharmacy at Celesio UK (which includes LloydsPharmacy) says: “Traditionally, patients will travel to their hospital every six months to receive their densosumab injections which we know can be inconvenient and time consuming. We also know that this can add to the capacity and cost challenges at many NHS Trusts. Through this partnership, we are offering patients an alternative that means they can get their treatment in the community, closer to home.”
The service was made available from 15th January 2018 to Queen Elizabeth Hospital Birmingham patients at the following three LloydsPharmacy stores:
Lloyds Pharmacy, 128/130 High Street, Kings Heath, Birmingham, B14 7LG
Lloyds Pharmacy, 18 Arden Road, Frankley, Birmingham, B45 0JA
Lloyds Pharmacy, 228 Wychall Road, Birmingham, B31 3AU
Jill continues: “Patients who require denosumab injections often experience pain from previous fractures. Our pharmacy teams have expertise in pain management, which means they can provide advice and support to help patients manage these conditions as part of the injection service.”
This service is part of the new LloydsPharmacy healthcare centre model which is designed to deliver more treatment in community pharmacy and in line with the UHB commitment in bringing patient care closer to home. Celesio UK is working in partnership with the NHS and manufacturers like Amgen to identify additional treatments which are suitable and able to be administered within LloydsPharmacy, outside a traditional acute hospital setting.
Jill adds: “This is a great opportunity to demonstrate the valuable role community pharmacy can play in supporting the NHS to meet patient needs. By working collaboratively alongside the Trust, we believe we can improve patient outcomes and boost efficiencies by carrying out services like this on their behalf.”
This patient service is partly funded by Amgen.
Notes to editors
LloydsPharmacy launched their healthcare centres model in December 2017 with a vision of delivering more treatment through community pharmacy and bringing care closer to patients’ homes.
This is part of Celesio UK’s transformational healthcare strategy, which aims to enhance the role of community pharmacy and offer more choice for patients. This involves working with NHS Trusts and other health organisations to identify ways to improve patient outcomes and drive efficiencies.
The LloydsPharmacy healthcare centres model is designed to give patients an alternative to traditional treatment settings, which would usually be at home or in a hospital.
These services include specialised medicine collection, subcutaneous injections, infusions clinics, as well as testing and screening. Each of these services can be delivered either within a traditional LloydsPharmacy store or in a dedicated LloydsPharmacy Healthcare Centre.
LloydsPharmacy healthcare centres utilises the expertise of both pharmacists and specially trained nurses from LloydsPharmacy Clinical Homecare.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.co.uk.